Cutaneous Disease as a Rare Presentation of Follicular Lymphoma Progression

Hassaan Jafri, MD1, Isna Khan, MD1, Noman Ahmed Jang Khan, MD1, Vincent Graffeo, MD1, Jennifer Hawkins, DO1, and Mohamed Alsharedi, MD1

Abstract
Follicular lymphoma, the third most common lymphoid malignancy, is considered indolent but incurable non-Hodgkin lymphoma. Isolated cutaneous relapse from follicular lymphoma is very uncommon, and very few cases have been reported in the literature. In this article, we present a case of an adult patient with a history of treated follicular lymphoma who presented with a skin lesion on his face and scalp. Further workup, including biopsy, led to the diagnosis of relapsed follicular lymphoma with no progression of disease elsewhere. We reviewed cases of follicular lymphoma, which relapsed with isolated cutaneous involvement. Treatment options for relapsed follicular lymphoma include observation, anti-CD 20 antibody alone, or in combination with chemotherapy, radio-immunotherapy, and stem cell transplantation in selected patients. Increased awareness of disease evolution and prompt diagnosis of this form of relapse from follicular lymphoma will improve the effectiveness and outcome of its management.

Keywords
follicular lymphoma, cutaneous

Introduction
Follicular lymphoma is considered an indolent but incurable non-Hodgkin lymphoma. It is the third most common lymphoid malignancy.1 Isolated cutaneous relapse from previously treated follicular lymphoma is a rare manifestation. We present a case of an adult patient with a history of previously treated follicular lymphoma who presented with a skin lesion. Usually cutaneous involvement by systemic lymphoma is easy to recognize as it manifests as rapidly growing and dull red to violaceous plaques/nodules. His skin lesions were in the form of subtle induration which is unusual for cutaneous involvement by systemic lymphoma.

Case Presentation
We present a case of a 64-year-old Caucasian male with a medical history considerable for chronic obstructive pulmonary disease and traumatic brain injury presented with worsening right inguinal area swelling for the past 5 years. The patient was asymptomatic otherwise. A computed tomography (CT) scan of the abdomen and pelvis was obtained first time in 2015, which demonstrated pelvic and abdominal lymphadenopathy. He was referred to surgery for an excisional biopsy, which revealed follicular lymphoma World Health Organization Grade I-II (Figure 1). Fluorescence in situ hybridization (FISH) was positive for IGH/BCL2 translocation t(14;18)(q32;q21). It was negative for MYC/IGH translocation and BCL6 rearrangement. It was determined at the time of diagnosis that the optimal therapy would be observation. One year later, the patient complained of generalized weakness as well as difficulty urinating due to obstructive uropathy secondary to lymph nodes that were identified on a CT scan of the abdomen and pelvis. Bone marrow biopsy was performed at that time and was positive for follicular lymphoma involving bone marrow (Figure 2). Morphology and flow cytometry were positive for 20% involvement by follicular lymphoma cells. Flow cytometry showed a large population of CD19-positive cells that co-express CD10. Neoplastic lymphocytes were positive for CD20 and expressed a kappa surface light chain in a restricted fashion. The FISH was positive for IGH/BCL2 translocation t(14;18)(q32;q21). After a discussion with the patient, he was given 4 weekly doses of rituximab in 2016, with subsequent CT scans showing an almost

1Marshall University Joan C. Edwards School of Medicine, Huntington, WV, USA

Received January 29, 2021. Revised January 29, 2021. Accepted February 1, 2021.

Corresponding Author:
Hassaan Jafri, MD, Marshall University Joan C. Edwards School of Medicine, 1400 Hal Greer Blvd, Huntington, WV 25701-3655, USA.
Email: hassaanjafriemd@gmail.com
Given some response and resolved obstructive uropathy, the patient was again placed under active surveillance with laboratory results and serial imaging to monitor for any relapse. He also had comorbidities and it was decided to hold off on any systemic treatment. During that period, the patient’s case was further complicated by an upper extremity deep vein thrombosis requiring oral anticoagulation as well as a lower extremity fracture requiring surgical repair. He also developed multiple squamous cell carcinomas (SCCs) of the face treated with local excision around 6 months after completion of rituximab therapy. There were no cell count abnormalities, B-symptoms, or radiological evidence of disease progression.

Two years after the patient received rituximab, he underwent Mohs microscopic surgery to remove a lesion on the right side of the face. The biopsy contained evidence of both SCC and follicular lymphoma (CD20+, CD10+ with BCL2 rearrangement by FISH) and no evidence of large cell transformation. Positron emission tomography (PET)/CT was done in November 2018, which was compared with

40% reduction in the size of the lymph nodes involved.
PET/CT done in September 2016 before first treatment. It showed the abdominal lymph nodes with some response from prior therapy, findings were still consistent with improvement compared with prior scans; however, on current PET/CT scan, there was new abnormal uptake on the left side of the scalp and soft tissue density along with the anterior right submandibular gland. There was uptake along left lateral scalp where there is scalp thickening measuring 10 mm with maximal SUV of 8.3. There was soft tissue density along anterior right submandibular gland which measured $1.5 \times 1.9$ cm and there was maximum SUV of 6.0. There was hypermetabolic activity within retroperitoneum with maximum SUV 10. This measured $2.4 \times 3.0$ cm and was previously larger and there was more extensive involvement. There were hypermetabolic lymph nodes in right common femoral region. Lymph node had maximum SUV 11.6 and the largest lymph node measured $1.9 \times 1.6$ cm. Previously there was more extensive lymphadenopathy in this location.

Given the new relapse involving extranodal sites, the patient was offered systemic therapy with rituximab and bendamustine. He ultimately refused chemotherapy and was treated again with 4 cycles of rituximab in January 2019. Interval PET/CT in April 2019, 8 weeks after therapy suggested complete response to treatment with resolved abdominal lymphadenopathy as well as improvement in the lesion of the right side of the patient’s scalp. As compared with previous PET/CT in November 2018, paraaortic and bilateral iliac lymphadenopathy had resolved. There was no abnormal hypermetabolic focus in abdomen and pelvis and no abnormal hypermetabolic activity was seen in the neck.

Three months later, he again developed swelling on the left side of his face (Figure 3). A biopsy was obtained and found positive for low-grade follicular lymphoma, Grade I-II (Figure 4). FISH was positive for translocation t(14;18)(q32;q21)/IGH-BCL2 rearrangement, consistent with the relapse. The patient was referred to radiation oncology for palliative radiation as he was initially refusing chemotherapy. Another PET/CT scan demonstrated skin thickening in the facial area, neck, scalp, and upper thorax with no evidence of disease elsewhere (Figure 5). Given the extent of illness, he was not deemed an appropriate candidate for radiation therapy. Accordingly, he agreed to be treated chemo-immunotherapy. The patient was started on bendamustine and rituximab. He had a good clinical response with improvement in his skin lesions.

Discussion

Follicular lymphoma is a prevalent B-cell malignancy characterized by sluggish growth patterns and frequent relapses. Almost 13960 cases of follicular lymphoma in United States were reported in 2016, making it the third most common lymphoid malignancy after diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia or small lymphocytic lymphoma. Incidence has been stable since the last decade.\(^1\) The most common presentation of follicular lymphoma is asymptomatic lymphadenopathy that waxes and wanes for years. Bone marrow involvement is commonly seen in 70% of cases. Other sites of involvement are less common.\(^2\)

There have been reported cases where non-Hodgkin lymphoma exclusively relapsed in the skin, but trials with follicular lymphoma have very rarely reported the cutaneous manifestation.\(^3\) Some of the cases described in the literature are mentioned in Table 1. Relapse occurred at the cutaneous site in our case, which was not involved primarily with no evidence of disease progression elsewhere.

One of the fascinating thing in our case is the predominant deep dermal/subcutaneous involvement with clear sparing of the upper dermis. Usually, cutaneous involvement in systemic B-cell lymphomas is easy to recognize, as it appears with rapidly growing, dull red to violaceous plaques/nodules,\(^4\) while in this case is a subtle pinkish induration of the face (Figure 3). Other differentials of his skin manifestation included rosacea and pseudolymphomas. It is evident from our reviewed cases that none of the patients presented like our patient (Table 1).

Skin lesions in the patient with a previous history of follicular warrants biopsy. Although rare, transformation

Figure 3. Figure shows large arrow as biopsy site. It has thick induration, which was biopsied as follicular lymphoma. The patient has fair skin phototype and clear signs of chronic solar damage (clearly observable in the neck area). Two asterisks showed possible actinic keratosis/squamous cell carcinomas.
to DLBCL as well as double hit B-cell lymphoma have been reported and will affect the management of the disease.\textsuperscript{5,6} Treatment of follicular lymphoma depends on the stage and grade of the disease. For localized disease, radiation is an effective option. In patients with the disseminated disease who are asymptomatic and have no cell count irregularities or end-organ damage, observation is a reasonable option. In symptomatic patients, treatment with anti-CD20 antibody with or without chemotherapy is recommended. Most of the patients have a good response, but recurrence is frequent.\textsuperscript{7} Patients who relapse can be treated with the same regimen. Stem cell transplant can be pursued in relapsed and refractory settings but carries high treatment-related mortality.\textsuperscript{7}

**Conclusion**

Our case will be a useful addition to the literature of rare cases with isolated cutaneous relapse in patients with a history of follicular lymphoma. We aim to alert the physicians and hematologists about an unusual cutaneous relapse of follicular lymphoma. They can have variable presentation ranging from rapidly growing nodules (which is more common) to subtle induration as in our patient. We suggest that cutaneous lesions in the patient with a history of lymphoma should be thoroughly investigated as they may be the only site of recurrence of the disease.
Table 1. Cases of Follicular Lymphoma Progression with Cutaneous Disease.

| Case                        | Time period for cutaneous presentation after initial diagnosis | Age | Gender | Clinical lesion                                                                 | Treatment                      | Outcome                          |
|-----------------------------|-----------------------------------------------------------------|-----|--------|----------------------------------------------------------------------------------|--------------------------------|-----------------------------------|
| Dhadlie and Strekozov⁴      | 8 years                                                         | 70  | Female | Sebaceous cyst like lesion on cheek                                                | Systemic therapy (not clear)   | Not clear                        |
| Talebi-Liasi and Sandhu⁴    | 3 years                                                         | 62  | Female | Ill-defined erythematous reticular patch with blanchable telangiectasias on scalp | Rituxan                        | Regressed after 4 cycles but new lesion appeared on cheek 3 months later |
| Rashid Dar et al⁸           | 17 years                                                        | 57  | Male   | Nodular lesion on right temple of the scalp                                      | RT                             | Complete remission                |
|                             | 20 years                                                        | 60  | Female | Multiple maculo-nodular of follicular-diffuse spots on the back of chest and shoulders | Tomography                     | Complete remission                |
| Lopez Aventin et al⁹        | 17 years                                                        | 81  | Female | Small, clustered, inconspicuous, slightly erythematous papules on the inner aspect of her left thigh | Not reported                   | Unknown                           |
| Ferrer et al¹⁰              | 5 years                                                         | 60  | Female | Multiple cutaneous nodules in the legs                                             | Rituxan 4 cycles               | Complete remission at 24 months follow-up |

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval
Our institution does not require ethical approval for reporting individual cases or case series.

Informed consent
Verbal Informed consent was obtained from the patient for their anonymized information including facial images to be published in this article.

ORCID iD
Hassaan Jafri https://orcid.org/0000-0003-1733-101X

References
1. Sutamtewagul G, Link BK. Novel treatment approaches and future perspectives in follicular lymphoma. Ther Adv Hematol. 2019;10:2040620718820510.
2. Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol. 2018;93:296-305.
3. Dhadlie S, Strekozov B. Cutaneous extra nodal lymphoma relapse: a case report and review of literature. Int J Surg Case Rep. 2018;51:306-308.
4. Talebi-Liasi F, Sandhu S. Rare presentation of disseminated follicular lymphoma as an ill-defined reticular patch over the scalp and forehead. JAAD Case Rep. 2019;5:319-322.
5. Palacios-Álvarez I, Román-Curto C, García-Sancho AM, et al. Cutaneous annular lesions as the first sign of transformation of follicular lymphoma into diffuse large B-cell lymphoma. Indian J Dermatol Venereol Leprol. 2015;81:495-497.
6. Magro CM, Wang X, Subramaniyam S, Darras N, Mathew S. Cutaneous double-hit B-cell lymphoma: an aggressive form of B-cell lymphoma with a propensity for cutaneous dissemination. Am J Dermatopathol. 2014;36:303-310.
7. Pavanello F, Steffanoni S, Ghielmini M, Zucca E. Systemic front-line therapy of follicular lymphoma: when, to whom and how. Mediterr J Hematol Infect Dis. 2016;8:e2016062.
8. Rashid Dar A, Jordan K, Yartsev S. Secondary cutaneous involvement in follicular diffuse lymphoma treated with helical tomotherapy. Cureus. 2017;9:e1471.
9. López Aventin D, García M, Pedro C, Pujol RM, Gallardo F. Miliary and agminated papules as clinical presentation of a secondary cutaneous follicular lymphoma. J Am Acad Dermatol. 2012;67:e195-e196.
10. Ferrer A, López-Guillermo A, Montoto S, Estrach T, Colomo L, Montserrat E. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab. Ann Hematol. 2001;80:479-481.